AGIO vs BMY
AGIO: Agios Pharmaceuticals is a rare disease-focused biopharmaceutical company advancing a pipeline of novel hematology and genetic disorder therapies, anchored by its pyruvate kinase activator, mitapivat. BMY: A leading biopharmaceutical innovator focused on discovering and delivering life-changing medicines to address serious illnesses globally.
Side-by-side fundamentals
| Metric | AGIO | BMY | Edge |
|---|---|---|---|
| Price as of 2026-07-31 close | $30.02 | $65.31 | |
| Market cap as of 2026-08-03 | $1.8B | $133.4B | |
| P/E as of 2026-08-03 | n/a | 19.42 | |
| PEG as of 2026-08-03 | n/a | -8.67 | |
| Net margin as of 2026-08-03 | -418.2% | +12.3% | BMY higher |
| Gross margin as of 2026-08-03 | +92.0% | +53.7% | AGIO higher |
| Operating margin as of 2026-08-03 | -466.8% | +17.1% | BMY higher |
| ROE as of 2026-08-03 | -35.7% | +41.6% | BMY higher |
| ROA as of 2026-08-03 | -33.1% | +8.7% | BMY higher |
| Debt / equity as of 2026-08-03 | 0.00 | 2.22 | AGIO lower |
| Revenue growth (YoY) as of 2026-08-03 | +140.6% | +1.8% | AGIO higher |
| Revenue CAGR (3y) SEC XBRL | +56.0% | +1.4% | AGIO higher |
| Dividend yield as of 2026-08-03 | n/a | +3.9% | |
| Dividend streak (yrs) SEC XBRL | n/a | 5 | |
| Beta as of 2026-08-03 | 1.04 | 0.24 | |
| 1-year return as of 2026-07-31 close | -19.3% | +50.8% | BMY higher |
Fundamentals: market data, as of 2026-08-03. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-31.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.